HANGZHOU, CHINA, Dec. 29, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical,” the “Company,” or “we”), a medical device supplier in China, via its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd., and its Chinese subsidiaries, today disclosed that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. (“Hunan Saitumofei”), has inked a one-year exclusive distribution agreement (the “Agreement”) with Shanghai Benke Medical Technology Co., Ltd. (“Shanghai Benke”) to promote and distribute its newly introduced AI-Automated Blood Cell Morphology Analyzer (CM-B600) (“Analyzer”) in East China for the entire year 2026. This partnership is anticipated to expedite market entry and spur the large-scale commercialization of the new product.
Under the Agreement, Hunan Saitumofei has bestowed upon Shanghai Benke exclusive distribution rights for the Analyzer in East China, encompassing Jiangsu Province, Shanghai Municipality, and Zhejiang Province — key markets within China’s vibrant Yangtze River Delta region — from Jan 1 to Dec 31, 2026. The Agreement sets a minimum annual sales target of RMB 10 million (approximately US$1.4 million). Shanghai Benke has made an advance payment of RMB 1 million as a performance bond, which will be subtracted from the final payment or returned interest-free upon reaching the sales target.
The Analyzer obtained manufacturing approval as a Class II medical device from a Chinese regulatory body in November 2025 and is compliant with relevant national and industry standards, such as GB 4793.1 and YY 0648. Leveraging high-resolution digital imaging technology, the Analyzer mimics the gold-standard workflow of manual microscopic inspection. By means of region-based level set segmentation and Support Vector Machine (SVM) algorithms, it automatically accomplishes sample scanning, identification, and classification.
Driven by advanced AI-automation, the Analyzer offers high imaging speed and classification accuracy. It can handle up to 150 samples per batch, with an extra emergency slot, achieving an average detection time of no more than three minutes per blood smear. The system attains a classification accuracy of no less than 90% for lymphocytes, neutrophils, eosinophils, basophils, and mature white blood cells per slide. Moreover, it can identify 17 subtypes of white blood cells and provides detailed morphological analyses of red blood cells (including acanthocytes, target cells, and fragments) as well as platelet characteristics (like size classification and aggregation identification). The Analyzer also supports a database capacity of over 350,000 high-definition blood cell images.
Notably, the Analyzer utilizes non-deep-learning feature extraction algorithms like nucleus-to-cytoplasm ratio and granularity analysis, providing high interpretability and significantly reducing potential clinical risks.
Mr. Shuang Wu, Chief Executive Officer and Chairman of WORK Medical, remarked: “We are delighted to announce this agency agreement shortly after obtaining manufacturing approval, which highlights both the Analyzer’s commercial readiness and the market’s recognition of our technology and brand. By leveraging Shanghai Benke’s well-established medical device sales network and its deep-seated presence in the East China market, we aim to expedite the Analyzer’s market penetration and further enhance WORK Medical’s nationwide brand standing. We are convinced that this rollout in East China will serve as a benchmark for wider adoption, laying a solid foundation for future expansion across China and into international markets.”
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, via its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd., and its Chinese subsidiaries, is a medical device supplier that develops and manufactures Class I and II medical devices and distributes Class I and II disposable medical devices through its operating subsidiaries in China. The company boasts a diverse product portfolio with 21 products, including customized and multifunctional masks and other medical consumables. All products have been sold in 34 provincial-level administrative regions in China, with 15 products available in over 30 countries globally. The company has received several quality-related manufacturing certifications and has registered 17 products with the U.S. Food and Drug Administration, enabling their entry into the U.S. market. For further information, please visit the company’s website: .
Forward-Looking Statements
This press release contains forward-looking statements, including those made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by terms like “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and similar expressions. Any statements in this press release that are not historical facts are deemed forward-looking. All forward-looking statements in this press release are based on the Company’s current expectations, estimates, and projections as of the release date and are subject to various risks and uncertainties that may cause actual results to differ materially from those stated or implied. While the Company believes the expectations in these forward-looking statements are reasonable, it cannot guarantee they will be accurate. The Company warns investors that actual results may differ significantly from anticipated results and encourages them to review other factors affecting future results in the Company’s Annual Report on Form 20-F and other documents filed with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update forward-looking statements unless required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
